Maria Loisiou

Learn More
BACKGROUND Development of a standardized platform for the rapid expansion of tumor-infiltrating lymphocytes (TILs) with anti-tumor function from patients with limited TIL numbers or tumor tissues challenges their clinical application. METHODS To facilitate adoptive immunotherapy, we applied genetically-engineered K562 cell-based artificial antigen(More)
  • 1